MedTrace Logo

APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat

NCT00100126 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2006-10-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of APC-231 QD for 7 days in the bacteriological outcome at the Test of Cure Visit.

Conditions

  • Pharyngitis

Interventions

DRUG

Amoxicillin Pulsatile Release Multiparticluate Sprinkle

Sponsors & Collaborators

  • Advancis Pharmaceutical Corporation

    lead INDUSTRY

Principal Investigators

  • Susan Clausen, PhD · Advancis Pharmaceutical Corp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100126 on ClinicalTrials.gov